TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03436537

Intervention type: OTHER
Intervention: Periodontal Aesthetic Perception Scale
Description: Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale

Intervention type: OTHER
Intervention: Periodontal Aesthetic Perception Scale
Description: Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale

Intervention type: OTHER
Intervention: Periodontal Aesthetic Perception Scale
Description: Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
Study: NCT00859235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate 0.2%
Description: Mouth wash prior to procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain water
Description: Mouth wash prior to procedure
Study: NCT03407573

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Red Cell
Description: Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Red Cell
Description: Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
Study: NCT04215380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Senegal extract
Description: Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pectin
Description: Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
Study: NCT00629837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
Description: Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
Description: High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
Study: NCT00301210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: oral doses four times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: oral doses four times per day
Study: NCT00725556

Intervention type: OTHER
Group type: OTHER
Intervention: Speech Therapy
Description: Speech Therapy
Study: NCT01992861

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Intervention: Diffusion Weighted Imaging
Description: Undergo DW MRI

Intervention type: PROCEDURE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: RADIATION
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MR spectroscopy

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study: NCT02955979

Intervention type: OTHER
Intervention: CT scan with iodinated contrast agents
Description: Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary.
Study: NCT00644280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
Study: NCT03830060

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of cortisol
Description: Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of cortisol
Description: Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
Study: NCT03170128

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient physical therapy in addition to standard follow-up visits
Description: Patients in Group 1 will be given a prescription for outpatient physical therapy.
Study: NCT03886207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ginger powder footbath
Description: 38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm water only footbath
Description: 38-40° C warm water footbath without any additive reaching up to mid-calf level
Study: NCT03840447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management programme
Description: The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens.
Study: NCT02215967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Description: 0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
Study: NCT03580473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SATURNO II association
Description: opthalmic solution, 4 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigadexa®
Description: opthalmic solution, 4 times a day
Study: NCT00321178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR4 - switch to CR4
Description: switch to oral treatment after 4 weeks SR 'standard' therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR4 - switch to CR4
Description: switch to oral treatment after 4 weeks SR 'standard' therapy
Study: NCT02977819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation practice
Description: 18 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning English as a foreign language
Description: 18 months
Study: NCT03170128

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises in addition to standard follow-up visits
Description: Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
Study: NCT02940288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
Study: NCT05294666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
Study: NCT01867827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback and Physical Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Study: NCT02591355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution injection
Description: Placebo is a saline solution
Study: NCT00070187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT00017147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: 120 mg/m\^2 IV over 1 hour on day 1 of each cycle
Study: NCT01761214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluroquinolones
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-lactamase inhibitor
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
Study: NCT02278107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tidal Assist Ventilator System
Description: Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula Oxygen
Description: Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
Study: NCT00003901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT05196841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anastatica Hierochuntica
Description: During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
Study: NCT02503332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study: NCT00520975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT04572074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided imagery
Description: 10 minutes of guided imagery experience

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 10 minutes of virtual reality experience
Study: NCT04426682

Intervention type: DIAGNOSTIC_TEST
Intervention: urodynamics parameters
Description: Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure.

Intervention type: DIAGNOSTIC_TEST
Intervention: urodynamics parameters
Description: Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure.
Study: NCT03999190

Intervention type: DRUG
Intervention: NPA radiotracer
Description: \[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

Intervention type: DRUG
Intervention: NPA radiotracer
Description: \[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

Intervention type: DRUG
Intervention: Raclopride radiotracer
Description: \[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

Intervention type: DRUG
Intervention: Raclopride radiotracer
Description: \[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

Intervention type: DRUG
Intervention: Dextroamphetamine
Description: Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

Intervention type: DRUG
Intervention: Dextroamphetamine
Description: Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
Study: NCT00555607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisolone
Description: Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
Study: NCT01895660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.
Study: NCT02174068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os
Study: NCT01524848

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: Two (2) tablets of 400 mg given once daily continuously
Study: NCT03103945

Intervention type: DEVICE
Intervention: CDS box connection of the Niobe™ Remote Magnetic Navigation System
Description: For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
Study: NCT01430299

Intervention type: DEVICE
Group type: OTHER
Intervention: Demineralized Bone Matrix
Description: Accell Evo3 in posteriolateral fusion (prospective cohort)

Intervention type: DEVICE
Group type: OTHER
Intervention: rh-BMP2
Description: rh-BMP2 in posterolateral fusion (retrospective cohort)
Study: NCT00895076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: iontophoretic patch and injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: iontophoretic patch and injection
Study: NCT02966197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic internal iliac artery balloon catheterization
Description: Between June 2015 and August 2016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic internal iliac artery balloon

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiology operation
Study: NCT05294666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months